Biodesix, Inc.

Integrated Diagnostics, Inc.

Xiao-Jun Li

Paul Edward Kearney

Clive Hayward

Kenneth Charles Fang

Miguel Dominguez Geeraerts

Douglas Spicer

Stephen W Hunsucker

Lik Wee Lee

Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Compositions, methods and kits for diagnosis of lung cancer

Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.

SRM methods in Alzheimer's disease and neurological disease assays

The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Selected reaction monitoring assays

Methods are provided for determining the expression level of target proteins in a subject. A plurality of respective peptide transitions are generated from a plurality of proteins obtained from a biological sample from the subject, wherein the plurality of proteins comprises both target and normalizing proteins. A mass spectroscopy (MS) signal intensity is measured from the plurality of respective peptide transitions and a plurality of corresponding stable isotope-labeled internal standard (SIS) peptide transitions. For each of the plurality of proteins, a response ratio is calculated between the MS signal intensity of the respective peptide transition and the corresponding SIS peptide transition. The response ratio for each target protein is normalized by a sample-dependent normalization factor calculated from the response ratio for each normalizing protein, wherein the normalized response ratios provide a determination of the expression level of the target proteins.

Integrated quantification method for protein measurements in clinical proteomics

Disclosed herein are novel diagnostic lung cancer panels and the use of these panels to diagnose, predict, and characterize lung cancer and to monitor or predict treatment efficacy.

Growing community of inventors

Bellevue, WA, United States of America

Xiao-Jun Li